Vasculitis & polymyalgia rheumatica
Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
Main finding · Relapse during and after TCZResult — go to the resultMultivariable aHR for relapse 0.01 95% CI 0.00–0.28Authors' conclusion
Long-term TCZ treatment was associated with remission maintenance in most patients with GCA. The estimated relapse rate by 18 months after TCZ discontinuation was 47.3%.
Study context
- Population
- Giant cell arteritis (GCA) patients treated with tocilizumab (TCZ) at a single centre (2010–2022)mean follow-up 3.1 years
- Participants
- 65 patients
- Exposure
- Periods on vs off TCZ; TCZ beyond 12 months vs stopping at or before 12 months
- Outcome
- Time to relapse and annualised relapse rate during and after TCZ treatment
Methodological detailssingle-centre
- Single-centre
Main finding
Relapse during and after TCZ
Multivariable aHR for relapse
0.01
95% CI 0.00–0.28
P = 0.005
As reported in the abstract
- Kaplan-Meier (KM)-estimated relapse rate at 18 months on TCZ
- 15.5%
- KM-estimated relapse rate at 18 months after TCZ discontinuation
- 47.3%
- Adjusted annualised relapse rate, all periods on TCZ
- 0.1 (95% CI 0.1 to 0.2)
- Adjusted annualised relapse rate, all periods off TCZ (95% CI 0.3 to 0.7); p=0.0004 vs on TCZ
- 0.4
Observational data: associations, not effects.
Further findings
First TCZ course discontinued for satisfactory remission
- Patients
- 45 (69.2%)
Prednisone discontinued
- Patients
- 76.9%
Patients receiving >1 TCZ course
- Patients
- 13
Safety
Serious adverse events
- 13 serious AEs in patients
- 11 (16.9%)
First TCZ course discontinued due to adverse events
- Patients
- 6 (9.2%)
Original publication
Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. RMD Open. Published 6 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →